Scott B. Ullem - May 7, 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, Chief Financial Officer
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
May 7, 2023
Transactions value $
-$415,126
Form type
4
Date filed
5/9/2023, 07:48 PM
Previous filing
May 4, 2023
Next filing
May 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $0 +6.06K +35.85% $0.00 23K May 7, 2023 Direct F1
transaction EW Common Stock Tax liability -$267K -3K -13.08% $88.74 20K May 7, 2023 Direct
transaction EW Common Stock Tax liability -$149K -1.67K -8.38% $88.74 18.3K May 8, 2023 Direct
holding EW Common Stock 258K May 7, 2023 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $0 -6.06K -78.47% $0.00 1.66K May 7, 2023 Common Stock 6.06K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.